Form 4: MAIA Biotechnology Director, Louie Ngar Yee, Reports Stock Option Grant

Director Louie Ngar Yee reports the acquisition of stock options in MAIA Biotechnology, Inc.

Summary

• On June 30, 2024, Louie Ngar Yee, a director of MAIA Biotechnology, Inc., was granted stock options to purchase 8,592 shares of common stock.
• The options were granted pursuant to the company's 2021 Equity Incentive Plan.
• The exercise price of the options is $3.42.
• The options vest immediately and are exercisable from the grant date.
• The options expire on June 30, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing related to executive compensation.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• Immediate vesting provides an incentive for continued service.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• Vesting schedules and exercise prices vary depending on company performance, industry norms, and individual negotiations.
• Comparing the terms of this grant (immediate vesting, $3.42 exercise price) to similar grants at comparable biotech firms would provide a benchmark for assessing its competitiveness and potential impact.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates